Assistant Professor of School of Population and Public Health at the University of British Columbia
Con to the question "Should Prescription Drugs Be Advertised Directly to Consumers?"
"Direct-to-consumer prescription drug advertising can cause damage by instigating rapid, widespread stimulation of use of new drugs before harmful effects are fully known.
Advertisements exaggerate treatment benefits and use emotive messages to target people with milder health problems, many of whom are unlikely to benefit from the drugs advertised.
Advertising leads to higher drug costs and overall health care costs through substitution of new, expensive drugs without treatment advantages."
"Should Canada Allow Direct-to-Consumer Advertising of Prescription Drugs? NO," Canadian Family Physician, www.cfp.ca, Feb. 2009
Experts Individuals with MDs, DOs, PhDs, MPHs, or equivalent advanced degrees in fields relevant to pharmaceutical drugs and public health; top-level federal government officials significantly involved in issues related to prescription drug advertising. [Note: Experts definition varies by site.]
Involvement and Affiliations:
Member, Health Action International (HAI-Europe) Board of Directors, 2013-2016
Consultant, Health Action International, 1996-present
Michael Smith Foundation for Health Research Scholar 2008-2014
Assistant Professor, School of Population and Public Health, University of British Columbia
Clinical Evidence Review Consultant, British Columbia Ministry of Health
Faculty Associate, Pharmaceutical Policy Unit at University of British Columbia's Centre for Health Services and Policy Research
Member, Steering Group of Women and Health Protection
Staff Member, Health Action International, 1991-1996
Former Visiting Scholar, Centre for Values, Ethics & Law in Medicine, Central Clinical School, University of Sydney, Australia
Former Model Curriculum Developer, Health Action International/World Health International
PhD, Health Care and Epidemiology, University of British Columbia